Assenagon Asset Management S.A. Sells 293,618 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

Assenagon Asset Management S.A. decreased its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 75.8% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 93,917 shares of the medical instruments supplier's stock after selling 293,618 shares during the period. Assenagon Asset Management S.A. owned approximately 0.12% of OraSure Technologies worth $578,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. AJOVista LLC bought a new stake in shares of OraSure Technologies in the 4th quarter valued at $39,000. Tocqueville Asset Management L.P. bought a new stake in shares of OraSure Technologies in the 3rd quarter valued at $75,000. Pathstone Family Office LLC bought a new stake in shares of OraSure Technologies in the 3rd quarter valued at $80,000. Dynamic Technology Lab Private Ltd acquired a new position in OraSure Technologies in the 4th quarter worth $113,000. Finally, Baader Bank Aktiengesellschaft bought a new position in OraSure Technologies during the 4th quarter worth about $115,000. Institutional investors own 93.50% of the company's stock.

OraSure Technologies Trading Up 3.1 %

Shares of NASDAQ OSUR traded up $0.15 during mid-day trading on Wednesday, hitting $5.05. The company had a trading volume of 1,156,732 shares, compared to its average volume of 880,169. The company has a market capitalization of $373.50 million, a PE ratio of 16.70 and a beta of 0.23. The firm has a 50-day simple moving average of $5.72 and a two-hundred day simple moving average of $6.80. OraSure Technologies, Inc. has a one year low of $4.38 and a one year high of $8.45.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The medical instruments supplier reported $0.04 earnings per share for the quarter, meeting the consensus estimate of $0.04. The company had revenue of $54.10 million during the quarter, compared to analysts' expectations of $52.27 million. OraSure Technologies had a return on equity of 7.68% and a net margin of 7.50%. OraSure Technologies's revenue for the quarter was down 65.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.37 EPS. Sell-side analysts expect that OraSure Technologies, Inc. will post -0.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

OSUR has been the subject of a number of research reports. StockNews.com cut OraSure Technologies from a "buy" rating to a "hold" rating in a report on Thursday, May 9th. JPMorgan Chase & Co. lowered their target price on OraSure Technologies from $7.00 to $6.00 and set a "neutral" rating for the company in a report on Monday, May 13th. Finally, Evercore ISI lowered their target price on OraSure Technologies from $7.00 to $6.50 and set an "in-line" rating for the company in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $6.63.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.